function
mediat
rna
interfer
rnai
small
interf
rna
sirna
doublestrand
rna
molecul
typic
nucleotid
length
consequ
molecular
weight
approxim
kd
neg
charg
consequ
passiv
transport
lipophil
cell
membran
poor
time
intracellular
entri
transloc
cytoplasm
andor
nucleu
rnai
machineri
locat
prerequisit
gene
silenc
activ
importantli
vivo
applic
intracellular
entri
target
cell
within
diseas
tissu
requir
lead
appear
cytoplasm
silenc
mrna
interest
figur
ideal
sirna
therefor
target
three
level
target
tissu
target
cell
type
subcellular
compart
primari
obstacl
achiev
vivo
includ
competit
uptak
nontarget
cell
excret
urin
degrad
nucleas
endosom
trap
literatur
report
claim
entri
sirna
target
cell
target
tissu
intraven
inject
observ
attribut
transloc
sirna
cell
membran
dsrnareceptor
refer
caenorhabd
elegan
respons
organ
system
spread
silenc
effect
inde
overexpress
mammalian
homologu
increas
intracellular
uptak
sirna
contrast
nake
sirna
use
mani
research
neg
control
fail
produc
silenc
effect
inject
vivo
even
prolong
incub
cell
high
sirna
concentr
vitro
lack
activ
nake
sirna
indic
cell
type
express
enough
homologu
observ
silenc
effect
addit
rapid
remov
nake
sirna
intraven
administr
circul
inject
dose
renal
excret
taken
liver
kupffer
cell
within
minut
make
small
percentag
administ
dose
avail
target
tissu
small
percentag
addit
subject
nucleas
degrad
therefor
intraven
inject
nake
sirna
reli
passiv
target
diseas
tissu
homologuemedi
target
cell
uptak
seem
ineffici
yet
unpredict
local
inject
site
patholog
avoid
mani
difficulti
encount
intraven
administr
notabl
rapid
elimin
therefor
popular
approach
increas
target
tissu
concentr
sirna
approach
chanc
obtain
suffici
intracellular
level
sirna
therapeut
effect
increas
furthermor
helper
molecul
like
cation
lipid
polym
physic
method
like
electropor
sonopor
hydrodynam
pressur
employ
facilit
intracellular
entranc
sirna
addit
local
product
sirna
gene
encod
short
hairpin
rna
shrna
ensur
prolong
level
dsrna
intracellularli
encod
gene
deliv
viral
vector
one
aforement
nonvir
method
unfortun
local
administr
alway
feasibl
target
tissu
reach
cover
area
larg
feasibl
local
inject
protocol
addit
use
local
inject
possibl
supplement
helper
molecul
physic
stimuli
select
deliveri
nontarget
target
cell
type
usual
taken
account
import
aspect
consid
nonspecif
effect
induc
dsrna
past
year
becom
clear
cell
respond
strongli
sirna
differ
proinflammatori
reaction
depend
cell
type
sirna
sequenc
intracellular
locat
effect
intensifi
employ
cation
helper
molecul
effect
probabl
mediat
chang
intracellular
traffick
dsrna
consequ
nontarget
cell
may
also
take
sirna
respond
induct
proinflammatori
pathway
addit
therapeut
rnai
effect
within
target
cell
diseas
site
review
focu
strategi
target
sirna
deliveri
design
improv
accumul
sirna
three
vivo
level
deliveri
target
tissu
target
cell
intracellular
target
site
action
concentr
deliveri
approach
system
administr
system
broadest
applic
three
approach
discuss
chemic
modif
sirna
viral
nucleic
acid
deliveri
system
nonvir
nucleic
acid
deliveri
system
attent
given
vivo
deliveri
strategi
vitro
target
studi
often
repres
fair
evalu
mani
barrier
exist
vivo
possibl
imped
effici
sitespecif
deliveri
eg
phagocyt
uptak
uptak
compet
cell
type
excret
intracellular
process
sirna
deliveri
system
stabil
chemic
modif
nucleobas
sugar
phosphat
ester
backbon
sirna
reduc
sirna
sensit
nucleas
initi
studi
center
toler
rnai
system
modif
two
rna
strand
number
chemic
modif
propos
increas
nucleas
resist
like
boranophosph
phosphorothio
fluorouridin
lock
nucleotid
chemic
modifi
sirna
still
abl
induc
sirnamedi
gene
silenc
provid
modif
absent
specif
region
sirna
includ
limit
extent
specif
restrict
regard
posit
degre
modif
depend
characterist
incorpor
modif
although
increas
nucleas
resist
sirna
would
expect
increas
vivo
silenc
effect
layzer
et
al
show
necessarili
case
studi
silenc
effect
liver
hydrodynam
inject
show
unmodifi
sirna
similar
potenc
stabil
version
contrast
chemic
modif
shown
enhanc
therapeut
effect
mous
model
hepat
b
viru
infect
chemic
modifi
sirna
design
conserv
region
hepat
b
viru
shown
decreas
viral
dna
hepat
b
surfac
antigen
level
serum
well
viral
rna
level
liver
compar
chemic
modifi
control
sirna
buffertr
anim
hydrodynam
inject
protocol
benefit
chemic
modifi
sirna
support
fact
indic
viral
infect
higher
anim
treat
unmodifi
sirna
sever
approach
develop
chemic
modif
introduc
enhanc
intracellular
uptak
sirna
liao
wang
develop
modifi
sirna
enhanc
lipophil
sirna
allow
passiv
diffus
cell
membran
time
enhanc
nucleas
resist
approach
investig
vitro
show
chemic
modif
enhanc
sirna
potenc
front
result
silenc
effect
chemic
modifi
sirna
specif
insulinlik
growth
factor
receptor
strongli
enhanc
compar
unmodifi
sirna
similar
setup
membran
permeant
peptid
penetratin
transportin
coupl
sirna
facilit
intracellular
uptak
coupl
peptid
via
reduc
disulfid
linker
bulki
peptid
expect
cleavedoff
liber
sirna
cytoplasm
approach
valid
vitro
thu
support
wide
applic
basic
technolog
nevertheless
cell
specif
lack
probabl
furthest
develop
work
chemic
modifi
sirna
report
soutcheck
et
al
develop
sirna
partial
phosphorothio
backbon
modif
sugar
variat
sens
antisens
strand
promot
nucleas
resist
time
cholesterol
conjug
end
sens
strand
use
pyrrolidin
linker
chang
tissu
distribut
cholesterolmodifi
sirna
silenc
report
gene
express
vitro
absenc
transfect
agent
someth
observ
unmodifi
sirna
probabl
interact
cholesterol
serum
compon
cultur
medium
improv
sirna
transloc
cellular
membran
cholesterol
modif
particularli
enhanc
bind
sirna
serum
albumin
probabl
explain
prolong
circul
halflif
measur
intraven
inject
compar
unmodifi
sirna
addit
prolong
presenc
circul
cholesterolmodifi
sirna
detect
liver
jejunum
concentr
ng
per
gram
tissu
hour
last
inject
mgkg
dose
level
suffici
reduc
level
apolipoprotein
plasma
reduct
parallel
reduct
overal
cholesterol
level
reduct
highdens
lipoprotein
low
densiti
lipoprotein
chylomicron
level
despit
impress
result
use
rel
simpl
modif
dose
chemic
modifi
sirna
need
rel
high
seem
underlin
chang
tissu
distribut
sirna
favor
target
cell
uptak
conjug
compar
small
chemic
group
difficult
achiev
time
small
molecular
weight
modif
seem
need
preserv
correct
interact
rnai
enzym
cleavabl
linker
coupl
bulkier
modif
may
approach
avoid
problem
conclus
chemic
modif
promis
import
advanc
regard
nucleas
resist
reduc
induct
stress
respons
invitrogen
develop
secondgener
sirna
known
stealth
rnai
chemic
modif
design
increas
specif
rnai
effect
allow
antisens
strand
effici
enter
rnai
pathway
elimin
induct
interferonrel
pathway
other
also
demonstr
sequenc
modif
strongli
influenc
intens
silenc
effici
inflammatori
reaction
provid
tool
optim
taken
togeth
chemic
modif
markedli
increas
nucleas
resist
sirna
improv
cellular
persist
conjug
translocatinghydrophob
function
group
increas
membran
permeat
strategi
affect
tissu
distribut
profil
sirna
chemic
modif
seem
difficult
approach
reconstitut
viral
envelop
deriv
influenza
viru
use
encapsul
deliv
sirna
reconstitut
membran
vesicl
contain
influenza
viru
spike
protein
hemagglutinin
addit
ad
cation
lipid
protein
respons
bind
fusion
cellular
membran
sirnaload
vesicl
taken
receptormedi
endocytosi
abl
escap
endosom
degrad
fusion
endosom
membran
function
sirna
deliveri
demonstr
vitro
vivo
uptak
macrophag
periton
caviti
demonstr
intraperiton
inject
similar
approach
describ
sirna
deliveri
simian
viru
particl
vitro
lymphoblastoid
cell
mani
viral
approach
drawback
system
difficulti
repeat
administr
limit
control
transduc
cell
type
wherea
viral
vector
possess
mani
desir
characterist
effici
nucleic
acid
deliveri
nonvir
vector
possess
sever
advantag
import
benefit
synthet
vector
system
safeti
relat
lack
immunogen
low
frequenc
integr
eas
largescal
product
addit
accommod
wide
varieti
nucleic
acid
size
allow
easi
modif
downsid
transfect
effici
limit
factor
face
weak
mani
function
group
need
incorpor
nonvir
nucleic
acid
deliveri
system
cation
function
group
usual
requir
bind
condens
nucleic
acid
therebi
protect
nucleas
import
sirna
increas
appar
molecular
weight
renal
clearanc
cutoff
addit
cation
compound
use
endosom
escap
enhanc
due
result
posit
charg
complex
tend
form
aggreg
bind
blood
stream
neg
charg
biomolecul
result
clearanc
usual
rapid
moreov
cation
complex
possess
propens
interact
virtual
cell
type
encount
creat
need
insul
interact
surfac
particl
promot
specif
purpos
shield
group
ad
enhanc
colloid
stabil
reduc
surfac
charg
therebi
avoid
nonspecif
cell
uptak
restor
cell
interact
targetspecif
manner
target
ligand
coupl
induc
sitespecif
bind
uptak
case
deliveri
dna
encod
shrna
nonvir
deliveri
system
nuclear
transloc
dna
often
inadequ
cytoplasm
site
activ
chemic
synthes
sirna
provid
import
advantag
system
consist
complet
rna
propos
guo
et
al
system
base
packag
rna
dnapackag
motor
bacteriophag
spontan
form
dimer
via
interlock
right
lefthand
loop
attach
sirna
one
loop
rna
aptam
cancer
cell
target
system
creat
could
silenc
survivin
gene
express
vitro
altern
system
could
also
target
folat
unshield
untarget
complex
sirna
cation
polym
lipid
provid
local
system
transfect
suffici
number
target
cell
therapeut
effect
sever
studi
employ
cation
lipid
complex
sirna
silenc
amongst
other
tnfalpha
intraperiton
macrophag
intraperiton
administr
delta
opioid
receptor
spinal
cord
dorsal
root
ganglia
intrathec
administr
pololik
bladder
cancer
intraves
administr
prostat
cancer
cell
intraven
administr
although
suffici
number
cell
must
reach
silenc
observ
fair
assum
larg
part
dose
arriv
nontarget
cell
view
nonspecif
effect
induc
cation
lipid
particular
combin
dsrna
may
sever
hamper
therapeut
applic
varieti
cation
compound
also
investig
sirnadeliveri
purpos
linear
low
molecular
weight
form
cation
polym
poli
ethylen
imin
pei
use
treatment
subcutan
implant
ovarian
carcinoma
mice
intraperiton
administr
complex
sirna
primarili
recov
muscl
liver
kidney
tumor
interestingli
major
organ
pei
nucleic
acidcomplex
usual
recov
lung
larg
avoid
importantli
silenc
polyplex
inhibit
ovarian
carcinoma
growth
vivo
atelocollagen
highli
purifi
typei
collagen
calf
dermi
digest
pepsin
shown
suitabl
vehicl
local
deliveri
sirna
addit
administ
intraven
atelocollagensirna
abl
local
site
tumor
mestastas
inhibit
metastasi
outgrowth
specif
tumor
level
increas
compar
level
nake
sirna
administr
ngmg
inject
sirna
effect
albeit
less
pronounc
also
seen
organ
investig
ie
liver
lung
kidney
spleen
demonstr
enhanc
tissu
uptak
exclus
tumorspecif
nevertheless
deliveri
level
sirna
silenc
enhanc
zest
gene
overexpress
hormonerefractori
metastat
prostat
cancer
phosphatidylinositol
regul
cell
surviv
prolifer
migrat
result
strong
inhibit
growth
bone
metastas
prostat
cancer
cell
importantli
sirnaatelocollagen
complex
fail
induc
nonspecif
proinflammatori
respons
like
secret
target
aminoacidbas
system
base
cation
peptid
protamin
system
protamineblock
cterminu
heavi
chain
fab
fragment
envelop
antibodi
coupl
form
protein
construct
known
system
highli
effici
bind
transfect
cell
express
hivenvelop
protein
although
unclear
hivenvelop
protein
would
intern
importantli
express
synthetas
indic
nonspecif
effect
increas
upon
sirna
transfect
hivenvelopeexpress
melanoma
cell
addit
cell
form
subcutan
tumor
vivo
cell
took
fluoresc
sirna
deliv
intraven
administr
nake
sirna
taken
deliv
cell
envelopeprotein
neg
deliveri
combin
sirna
cmyc
vegf
strongli
inhibit
tumor
growth
vivo
deliv
use
system
combin
sirna
attack
tumor
multipl
front
import
advantag
sirna
technolog
allow
simultan
interfer
number
differ
pathway
deliveri
problem
individu
drug
molecul
sirna
remain
versatil
target
system
demonstr
exchang
hivenvelop
antibodi
chang
specif
system
breast
carcinoma
cell
cation
lipidbas
approach
pirollo
et
al
coupl
transferrin
receptor
singl
chain
fv
region
antibodi
fragment
surfac
cation
dotap
dope
complex
contain
sirna
evalu
target
potenti
system
differ
murin
tumor
model
orthothop
implant
pancreat
carcinoma
produc
spontan
metastas
orthotop
implant
prostat
carcinoma
intraven
administ
breast
carcinoma
cell
give
rise
metastas
lung
model
specif
accumul
fluoresc
label
sirna
complex
target
cation
lipid
particl
site
malign
could
demonstr
compar
surround
normal
tissu
liver
question
whether
target
deliveri
result
gene
silenc
address
target
cation
system
import
advantag
possess
recognit
signal
specif
interact
target
cell
type
howev
cation
surfac
may
also
abl
interact
biomolecul
nontarget
cell
shield
cation
surfac
may
enhanc
target
cell
specif
reduc
nontarget
tissu
uptak
may
addit
increas
colloid
stabil
sirna
complex
studi
focus
cation
polym
pei
coupl
peg
shield
polym
distal
end
pegchain
cyclic
rgdpeptid
coupl
peptid
highaffin
ligand
alpha
vintegrin
overexpress
angiogen
endotheli
surfac
tissu
distribut
studi
vivo
fluoresc
label
sirna
subcutan
neuroblastomabear
mice
show
inject
nake
sirna
produc
appreci
tumor
level
rather
rapid
clearanc
urin
peisirna
complex
also
lack
product
high
fluoresc
tumor
increas
liver
especi
lung
level
fluoresc
appear
punctuat
latter
tissu
probabl
reflect
format
aggreg
circul
pegshield
target
nanoparticl
use
higher
level
specif
tumor
lower
level
fluoresc
lung
liver
observ
therapeut
set
sirna
murin
vegf
use
sinc
receptor
one
drive
factor
tumor
angiogenesi
deliveri
host
tumor
endothelium
requir
inhibit
tumor
prolifer
efficaci
studi
sirna
complex
rgdpegpei
nanoparticl
result
strong
inhibit
sc
neuroblastoma
growth
rate
sequencespecif
experi
suggest
target
shield
nanoparticl
inde
deliv
sirna
angiogen
endotheli
cell
line
find
reduc
tumor
growth
rate
parallel
reduct
blood
vessel
peripheri
tumor
chang
vascular
morpholog
remain
vessel
support
antiangiogen
mechan
action
result
support
studi
model
patholog
angiogenesi
eye
demonstr
vasculaturespecif
deliveri
inhibit
angiogenesi
lead
therapeut
effect
importantli
studi
eye
also
show
combin
sirna
differ
drive
factor
vegfpathway
deliveri
system
improv
therapeut
effect
attack
variou
receptor
growth
factor
simultan
seem
offer
advantag
especi
multifactori
diseas
function
redund
like
cocktail
approach
seem
offer
import
benefit
synthet
nonvir
deliveri
system
divers
class
molecul
use
differ
nucleic
acid
deliveri
strategi
rang
rel
simpl
cation
complex
local
administr
target
shield
system
intraven
inject
adapt
specif
target
requir
import
advantag
although
optim
deliveri
effici
continu
remain
import
last
decad
research
promis
nucleic
acid
therapeut
intervent
difficulti
encount
turn
promis
clinic
realiti
provid
clearer
pictur
develop
step
need
transform
nucleic
acid
actual
drug
molecul
result
sirna
abl
make
remark
rapid
progress
initi
discoveri
function
mediat
rna
interfer
mammalian
cell
three
clinic
trial
end
two
agerel
macular
degener
respiratori
syncyti
viru
infect
nevertheless
choic
diseas
also
reflect
deliveri
difficulti
encount
class
nucleic
acid
diseas
select
partli
target
cell
deliveri
problem
rel
low
patholog
confin
specif
access
site
improv
target
specif
also
view
possibl
advers
effect
occur
sirna
process
nontarget
cell
allow
applic
sirna
system
treatment
sever
strategi
propos
figur
taken
togeth
serv
increas
nucleas
resist
reduc
renal
excretionspecif
cell
uptak
promot
uptak
target
cell
ensur
correct
intracellular
traffick
site
action
first
preclin
proof
principl
deliv
show
therapeut
effect
local
system
deliv
sirna
expect
strategi
soon
translat
viabl
clinic
develop
program
